Indivior (NASDAQ:INDV) Now Covered by Rodman & Renshaw

Analysts at Rodman & Renshaw began coverage on shares of Indivior (NASDAQ:INDV) in a research note issued to investors on Tuesday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $16.00 price target on the stock. Rodman & Renshaw’s price objective would suggest a potential upside of 33.11% from the stock’s previous close.

Other equities analysts have also issued research reports about the company. Piper Sandler restated an “overweight” rating and set a $16.00 price target (up previously from $15.00) on shares of Indivior in a research note on Friday, October 25th. Craig Hallum reduced their price target on shares of Indivior from $20.00 to $16.00 and set a “buy” rating for the company in a report on Friday, October 11th.

Indivior Stock Performance

Indivior stock opened at $12.02 on Tuesday. Indivior has a fifty-two week low of $7.33 and a fifty-two week high of $23.22. The company has a market capitalization of $1.66 billion, a PE ratio of -300.42 and a beta of 0.74. The company has a 50 day moving average price of $11.64 and a 200-day moving average price of $11.00.

Hedge Funds Weigh In On Indivior

Several hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Indivior during the 4th quarter worth about $56,000. Stifel Financial Corp acquired a new position in Indivior in the 3rd quarter worth approximately $100,000. Melqart Asset Management UK Ltd acquired a new stake in Indivior during the 3rd quarter valued at approximately $132,000. Jane Street Group LLC purchased a new stake in shares of Indivior in the 3rd quarter valued at $180,000. Finally, Public Employees Retirement System of Ohio acquired a new stake in shares of Indivior in the third quarter worth $294,000. 60.33% of the stock is owned by institutional investors and hedge funds.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.